Prognostic impact of atrial fibrillation and atrial flutter in patients with non-ST-segment elevation acute coronary syndrome.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Pablo Bazal-Chacón, Emilio Blanco-López, Pedro Cepas-Guillén, Felipe Díez-Delhoyo, Pablo Díez-Villanueva, Ane Elorriaga, Alfonso Jurado-Román, María Thiscal López-Lluva, Martín Negreira-Caamaño, Iván Olavarri-Miguel, Ricardo Rivera-López

Ngôn ngữ: eng

Ký hiệu phân loại: 616.858841 Diseases of nervous system and mental disorders

Thông tin xuất bản: Spain : Revista espanola de cardiologia (English ed.) , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 123021

 INTRODUCTION AND OBJECTIVES: Arrhythmias such as atrial fibrillation and atrial flutter (AF/AFl) complicate the management of patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). The aim of this study was to analyze the prognostic impact of AF/AFl in this clinical setting. METHODS: The IMPACT-TIMING-GO is a prospective, multicenter registry that enrolled patients with NSTEACS undergoing invasive management. In this subanalysis, patients were categorized based on the presence of AF/AFl (either pre-existing or occurring during admission). Clinical management and complications were assessed both during hospitalization (using a composite endpoint of death, renal failure, ventricular arrhythmias, delirium, new infarction, mechanical complications, and major bleeding) and after 1 year of follow-up (using a composite endpoint of death, cardiovascular admissions, and major bleeding). RESULTS: A total of 1020 patients (mean age, 66.8 ± 12.7 years
  23.5% women) were included. Of these, 79 (7.7%) had prior AF/AFl, and 37 (3.6%) developed de novo AF/AFl during admission. Patients with AF/AFl were older and had a higher comorbidity burden, with de novo AF/AFl being associated with greater clinical severity. After multivariate adjustment, only de novo AF/AFl, and not previous AF/AFl, was independently associated with the composite endpoint of in-hospital complications (OR, 5.12
  95%CI, 2.30-11.43
  P <
  .001 vs OR, 1.70, 95%CI, 0.91-3.58
  P = .166) and adverse events at 1 year (HR, 1.95
  95%CI, 1.02-3.76
  P = .045 vs HR, 1.02, 95%CI, 0.55-5.86
  P = .957). CONCLUSIONS: In patients with NSTEACS, de novo AF/AFl is independently associated with higher rates of both in-hospital and follow-up complications. Full English text available from: www.revespcardiol.org/en.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH